272 related articles for article (PubMed ID: 29473656)
1. α-synuclein (SNCA) but not dynamin 3 (DNM3) influences age at onset of leucine-rich repeat kinase 2 (LRRK2) Parkinson's disease in Spain.
Fernández-Santiago R; Garrido A; Infante J; González-Aramburu I; Sierra M; Fernández M; Valldeoriola F; Muñoz E; Compta Y; Martí MJ; Ríos J; Tolosa E; Ezquerra M;
Mov Disord; 2018 Apr; 33(4):637-641. PubMed ID: 29473656
[TBL] [Abstract][Full Text] [Related]
2. SNCA but not DNM3 and GAK modifies age at onset of LRRK2-related Parkinson's disease in Chinese population.
Yang ZH; Li YS; Shi MM; Yang J; Liu YT; Mao CY; Fan Y; Hu XC; Shi CH; Xu YM
J Neurol; 2019 Jul; 266(7):1796-1800. PubMed ID: 31041581
[TBL] [Abstract][Full Text] [Related]
3. DNM3 and genetic modifiers of age of onset in LRRK2 Gly2019Ser parkinsonism: a genome-wide linkage and association study.
Trinh J; Gustavsson EK; Vilariño-Güell C; Bortnick S; Latourelle J; McKenzie MB; Tu CS; Nosova E; Khinda J; Milnerwood A; Lesage S; Brice A; Tazir M; Aasly JO; Parkkinen L; Haytural H; Foroud T; Myers RH; Sassi SB; Hentati E; Nabli F; Farhat E; Amouri R; Hentati F; Farrer MJ
Lancet Neurol; 2016 Nov; 15(12):1248-1256. PubMed ID: 27692902
[TBL] [Abstract][Full Text] [Related]
4. No association of DNM3 with age of onset in Asian Parkinson's disease.
Foo JN; Tan LC; Au WL; Prakash KM; Liu J; Tan EK
Eur J Neurol; 2019 May; 26(5):827-829. PubMed ID: 30133089
[TBL] [Abstract][Full Text] [Related]
5. No evidence for DNM3 as genetic modifier of age at onset in idiopathic Parkinson's disease.
Berge-Seidl V; Pihlstrøm L; Wszolek ZK; Ross OA; Toft M
Neurobiol Aging; 2019 Feb; 74():236.e1-236.e5. PubMed ID: 30340792
[TBL] [Abstract][Full Text] [Related]
6. Analysis of DNM3 and VAMP4 as genetic modifiers of LRRK2 Parkinson's disease.
Brown EE; Blauwendraat C; Trinh J; Rizig M; Nalls MA; Leveille E; Ruskey JA; Jonvik H; Tan MMX; Bandres-Ciga S; Hassin-Baer S; Brockmann K; Infante J; Tolosa E; Ezquerra M; Ben Romdhan S; Benmahdjoub M; Arezki M; Mhiri C; Hardy J; Singleton AB; Alcalay RN; Gasser T; Grosset DG; Williams NM; Pittman A; Gan-Or Z; Fernandez-Santiago R; Brice A; Lesage S; Farrer M; Wood N; Morris HR;
Neurobiol Aging; 2021 Jan; 97():148.e17-148.e24. PubMed ID: 32873436
[TBL] [Abstract][Full Text] [Related]
7. Age at onset in LRRK2-associated PD is modified by SNCA variants.
Botta-Orfila T; Ezquerra M; Pastor P; Fernández-Santiago R; Pont-Sunyer C; Compta Y; Lorenzo-Betancor O; Samaranch L; Martí MJ; Valldeoriola F; Calopa M; Fernández M; Aguilar M; de Fabregas O; Hernández-Vara J; Tolosa E
J Mol Neurosci; 2012 Sep; 48(1):245-7. PubMed ID: 22669510
[TBL] [Abstract][Full Text] [Related]
8. Differential Phospho-Signatures in Blood Cells Identify LRRK2 G2019S Carriers in Parkinson's Disease.
Garrido A; Santamaría E; Fernández-Irigoyen J; Soto M; Simonet C; Fernández M; Obiang D; Tolosa E; Martí MJ; Padmanabhan S; Malagelada C; Ezquerra M; Fernández-Santiago R
Mov Disord; 2022 May; 37(5):1004-1015. PubMed ID: 35049090
[TBL] [Abstract][Full Text] [Related]
9. LRRK2 G2019S Mutation Inhibits Degradation of α-Synuclein in an In Vitro Model of Parkinson's Disease.
Hu D; Niu JY; Xiong J; Nie SK; Zeng F; Zhang ZH
Curr Med Sci; 2018 Dec; 38(6):1012-1017. PubMed ID: 30536063
[TBL] [Abstract][Full Text] [Related]
10. SNCA and mTOR Pathway Single Nucleotide Polymorphisms Interact to Modulate the Age at Onset of Parkinson's Disease.
Fernández-Santiago R; Martín-Flores N; Antonelli F; Cerquera C; Moreno V; Bandres-Ciga S; Manduchi E; Tolosa E; Singleton AB; Moore JH; ; Martí MJ; Ezquerra M; Malagelada C
Mov Disord; 2019 Sep; 34(9):1333-1344. PubMed ID: 31234232
[TBL] [Abstract][Full Text] [Related]
11. Cerebrospinal fluid biomarkers and clinical features in leucine-rich repeat kinase 2 (LRRK2) mutation carriers.
Vilas D; Shaw LM; Taylor P; Berg D; Brockmann K; Aasly J; Marras C; Pont-Sunyer C; Ríos J; Marek K; Tolosa E
Mov Disord; 2016 Jun; 31(6):906-14. PubMed ID: 27041685
[TBL] [Abstract][Full Text] [Related]
12. Evaluating the Role of SNCA, LRRK2, and GBA in Chinese Patients With Early-Onset Parkinson's Disease.
Chen Y; Gu X; Ou R; Zhang L; Hou Y; Liu K; Cao B; Wei Q; Li C; Song W; Zhao B; Wu Y; Cheng J; Shang H
Mov Disord; 2020 Nov; 35(11):2046-2055. PubMed ID: 32677286
[TBL] [Abstract][Full Text] [Related]
13. Genotype-phenotype relations for the Parkinson's disease genes SNCA, LRRK2, VPS35: MDSGene systematic review.
Trinh J; Zeldenrust FMJ; Huang J; Kasten M; Schaake S; Petkovic S; Madoev H; Grünewald A; Almuammar S; König IR; Lill CM; Lohmann K; Klein C; Marras C
Mov Disord; 2018 Dec; 33(12):1857-1870. PubMed ID: 30357936
[TBL] [Abstract][Full Text] [Related]
14. Assessment of risk factor variants of LRRK2, MAPT, SNCA and TCEANC2 genes in Hungarian sporadic Parkinson's disease patients.
Boros FA; Török R; Vágvölgyi-Sümegi E; Pesei ZG; Klivényi P; Vécsei L
Neurosci Lett; 2019 Jul; 706():140-145. PubMed ID: 31085292
[TBL] [Abstract][Full Text] [Related]
15. Resequencing analysis of five Mendelian genes and the top genes from genome-wide association studies in Parkinson's Disease.
Benitez BA; Davis AA; Jin SC; Ibanez L; Ortega-Cubero S; Pastor P; Choi J; Cooper B; Perlmutter JS; Cruchaga C
Mol Neurodegener; 2016 Apr; 11():29. PubMed ID: 27094865
[TBL] [Abstract][Full Text] [Related]
16. Role of LRRK2 and SNCA in autosomal dominant Parkinson's disease in Turkey.
Kessler C; Atasu B; Hanagasi H; Simón-Sánchez J; Hauser AK; Pak M; Bilgic B; Erginel-Unaltuna N; Gurvit H; Gasser T; Lohmann E
Parkinsonism Relat Disord; 2018 Mar; 48():34-39. PubMed ID: 29248340
[TBL] [Abstract][Full Text] [Related]
17. Autosomal dominant Parkinson's disease: Incidence of mutations in LRRK2, SNCA, VPS35 and GBA genes in Brazil.
Abreu GM; Valença DC; Campos M; da Silva CP; Pereira JS; Araujo Leite MA; Rosso AL; Nicaretta DH; Vasconcellos LF; da Silva DJ; Della Coletta MV; Dos Santos JM; Gonçalves AP; Santos-Rebouças CB; Pimentel MM
Neurosci Lett; 2016 Dec; 635():67-70. PubMed ID: 27777137
[TBL] [Abstract][Full Text] [Related]
18. Methylation of α-synuclein and leucine-rich repeat kinase 2 in leukocyte DNA of Parkinson's disease patients.
Tan YY; Wu L; Zhao ZB; Wang Y; Xiao Q; Liu J; Wang G; Ma JF; Chen SD
Parkinsonism Relat Disord; 2014 Mar; 20(3):308-13. PubMed ID: 24398085
[TBL] [Abstract][Full Text] [Related]
19. Dyskinesias in patients with Parkinson's disease: effect of the leucine-rich repeat kinase 2 (LRRK2) G2019S mutation.
Yahalom G; Kaplan N; Vituri A; Cohen OS; Inzelberg R; Kozlova E; Korczyn AD; Rosset S; Friedman E; Hassin-Baer S
Parkinsonism Relat Disord; 2012 Nov; 18(9):1039-41. PubMed ID: 22703868
[TBL] [Abstract][Full Text] [Related]
20. Penetrance estimate of LRRK2 p.G2019S mutation in individuals of non-Ashkenazi Jewish ancestry.
Lee AJ; Wang Y; Alcalay RN; Mejia-Santana H; Saunders-Pullman R; Bressman S; Corvol JC; Brice A; Lesage S; Mangone G; Tolosa E; Pont-Sunyer C; Vilas D; Schüle B; Kausar F; Foroud T; Berg D; Brockmann K; Goldwurm S; Siri C; Asselta R; Ruiz-Martinez J; Mondragón E; Marras C; Ghate T; Giladi N; Mirelman A; Marder K;
Mov Disord; 2017 Oct; 32(10):1432-1438. PubMed ID: 28639421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
